Graefen M - Search Results

1

Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients.

Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, Shariat SF, Tilki D, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Hoeh B, et al. Among authors: graefen m. Front Oncol. 2021 Nov 23;11:778858. doi: 10.3389/fonc.2021.778858. eCollection 2021. Front Oncol. 2021. PMID: 34888250 Free PMC article.

2

Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.

Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Huland E, Scardino PT, Kattan MW, Huland H. Graefen M, et al. J Urol. 2002 Mar;167(3):1306-9. J Urol. 2002. PMID: 11832719

3

Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer.

Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian PA, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, Scardino PT, Kattan MW. Graefen M, et al. J Clin Oncol. 2002 Feb 15;20(4):951-6. doi: 10.1200/JCO.2002.20.4.951. J Clin Oncol. 2002. PMID: 11844816

4

Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement?

Cagiannos I, Graefen M, Karakiewicz PI, Ohori M, Eastham JA, Rabbani F, Fair W, Wheeler TM, Hammerer PG, Haese A, Erbersdobler A, Huland H, Scardino PT, Kattan MW. Cagiannos I, et al. Among authors: graefen m. J Clin Oncol. 2002 Apr 15;20(8):2025-30. doi: 10.1200/JCO.2002.08.123. J Clin Oncol. 2002. PMID: 11956261

5

Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer.

Palisaar RJ, Graefen M, Karakiewicz PI, Hammerer PG, Huland E, Haese A, Fernandez S, Erbersdobler A, Henke RP, Huland H. Palisaar RJ, et al. Among authors: graefen m. Eur Urol. 2002 Feb;41(2):155-61. doi: 10.1016/s0302-2838(01)00025-2. Eur Urol. 2002. PMID: 12074402

6

International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy.

Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Klein E, Kupelian P, Skinner DG, Lieskovsky G, Bochner B, Huland H, Hammerer PG, Haese A, Erbersdobler A, Eastham JA, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, van der Kwast TH, Scardino PT, Kattan MW. Graefen M, et al. J Clin Oncol. 2002 Aug 1;20(15):3206-12. doi: 10.1200/JCO.2002.12.019. J Clin Oncol. 2002. PMID: 12149292

7

A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men.

Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Fernandez S, Noldus J, Erbersdobler A, Huland H, Scardino PT, Kattan MW. Graefen M, et al. Urol Oncol. 2002 Jul-Aug;7(4):141-6. doi: 10.1016/s1078-1439(02)00177-1. Urol Oncol. 2002. PMID: 12474529

8

Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables.

Graefen M, Augustin H, Karakiewicz PI, Hammerer PG, Haese A, Palisaar J, Blonski J, Fernandez S, Erbersdobler A, Huland H. Graefen M, et al. Eur Urol. 2003 Jan;43(1):6-10; discussion 11. doi: 10.1016/s0302-2838(02)00497-9. Eur Urol. 2003. PMID: 12507538

9

Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer.

Augustin H, Eggert T, Wenske S, Karakiewicz PI, Palisaar J, Daghofer F, Huland H, Graefen M. Augustin H, et al. Among authors: graefen m. J Urol. 2004 Jan;171(1):177-81. doi: 10.1097/01.ju.0000099827.77355.a7. J Urol. 2004. PMID: 14665871

10

Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer.

Graefen M, Ohori M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Erbersdobler A, Henke RP, Huland H, Wheeler TM, Slawin K, Scardino PT, Kattan MW. Graefen M, et al. J Urol. 2004 Jan;171(1):200-3. doi: 10.1097/01.ju.0000099161.70713.c8. J Urol. 2004. PMID: 14665876

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

952 results

Search Page

Filters